Merck & Co., Inc. (MRK) News
Follow Merck & Co., Inc. (MRK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 265 public stories across 67 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
FDA Authorizes Bravecto for New World Screwworm in Dogs
The FDA issued an emergency use authorization for Bravecto (fluralaner) to treat New World screwworm infestations in dogs and puppies.
REGULATION | Nov 03, 2026, 08:46 PM UTC
M
Lonza to Buy Five Merck Sites, More Than Doubling U.S. Presence
Lonza is buying five sites from Germany’s Merck to more than double its presence in the United States.
MNA | Nov 03, 2026, 11:54 AM UTC
M
Lonza to Buy Five U.S. Manufacturing Sites From Merck KGaA
Lonza agreed to buy five U.S. manufacturing sites from Merck KGaA, more than doubling its U.S. footprint. The deal will bring Lonza’s U.S. site count to nine.
MNA | Nov 03, 2026, 09:14 AM UTC
M
Merck Agrees to Sell CDMO Business to Lonza
Merck agreed to sell its CDMO business to Lonza.
MNA | Nov 03, 2026, 06:50 AM UTC
M
Merck to Divest CDMO Business to Lonza
MNA | Nov 03, 2026, 06:46 AM UTC
M
Lonza Agrees to Buy Five U.S. Drug Manufacturing Sites From Merck
Lonza Group agreed to acquire five U.S. contract drug manufacturing sites from Germany's Merck KGaA. The deal size was not disclosed.
MNA | Nov 03, 2026, 06:43 AM UTC
M
Lonza to Buy Five CDMO Manufacturing Sites From Merck KGaA
MNA | Nov 03, 2026, 06:07 AM UTC
M
Lonza to Buy U.S. CDMO Network From Merck KGaA
MNA | Nov 03, 2026, 06:06 AM UTC
M
MRK Reports Fiscal Q3 Net Loss
MRK reported a fiscal third-quarter net loss attributable to shareholders, down 103.34% year over year.
EQUITY | Oct 30, 2026, 05:45 AM UTC
M
PharmaMar Reports First-Nine-Month Net Income Down 43% to €8.7 Million
EARNINGS | Oct 29, 2026, 04:50 PM UTC
M
Merck Plans to Raise Revenue Forecast for Next Decade
Merck plans to raise its revenue forecast for the next decade, citing optimism about new medicines.
EARNINGS | Oct 29, 2026, 03:50 PM UTC
M
Keytruda Maker Reports Third-Quarter Profit Above Expectations
The pharmaceutical company reported third-quarter profit above expectations.
EQUITY | Oct 29, 2026, 03:42 PM UTC
M
Merck Raises Annual Profit Forecast After Topping Q3 Results
Merck shares rose after the company raised its annual profit forecast and reported Q3 results that topped expectations.
EQUITY | Oct 29, 2026, 02:20 PM UTC
M
Merck Executive Expects to Raise Mid-2030s Revenue Forecast
A Merck executive said the company now expects to raise its forecast of $70 billion in revenue in the mid-2030s, citing new growth drivers.
EARNINGS | Oct 29, 2026, 02:03 PM UTC
M
Merck tops third-quarter forecasts on strong Keytruda and Gardasil results
Merck exceeded forecasts for the third quarter, citing strong results from Keytruda and Gardasil.
EARNINGS | Oct 29, 2026, 01:48 PM UTC
M
Merck shares rise 3.2% after topping third-quarter estimates
EARNINGS | Oct 29, 2026, 01:32 PM UTC
M
Merck Executive Says Generic Competition, LOE to Offset Growth by Over $2 Billion
A Merck executive said growth will be partially offset by more than $2 billion of headwinds from generic competition and loss of exclusivity.
EARNINGS | Oct 29, 2026, 01:32 PM UTC
M
Merck Says Keytruda Sales Rose 6% to $8.6 Billion in Q3
Keytruda generated nearly half of Merck’s worldwide sales in the third quarter. Merck attributed the drug’s growth to uptake in earlier-stage indications and its new Qlex form.
EARNINGS | Oct 29, 2026, 01:30 PM UTC
M
Merck Executive Expects Moderate Top-Line Growth in 2027
A Merck executive said on a conference call that the company expects moderate top-line growth in 2027.
EARNINGS | Oct 29, 2026, 01:30 PM UTC
M
Merck Beats Third-Quarter Forecasts on Keytruda and Gardasil
Merck's third-quarter results exceeded forecasts, supported by strong performance from Keytruda and Gardasil.
EARNINGS | Oct 29, 2026, 12:26 PM UTC
M
Merck Beats Third-Quarter Expectations as Keytruda and Gardasil Outperform
Merck exceeded third-quarter expectations, with Keytruda and Gardasil performing better than expected.
EARNINGS | Oct 29, 2026, 12:26 PM UTC
M
Merck Opens South Korean Bioprocessing Center With Investment Exceeding €300 Million
Merck opened a bioprocessing center in South Korea after an investment exceeding €300 million.
EQUITY | Oct 29, 2026, 12:21 PM UTC
M
Merck Expects Underlying Operating Expenses to Rise Mid- to High-Single Digits in 2027
EARNINGS | Oct 29, 2026, 11:45 AM UTC
L
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, L3Harris, Eli Lilly
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, L3Harris, Eli Lilly Workspace search string for individual s
EQUITY | Oct 29, 2026, 11:42 AM UTC
L
Merck Reports Third-Quarter EPS of $2.04
EARNINGS | Oct 29, 2026, 10:55 AM UTC
M
Merck raises 2026 adjusted earnings-per-share guidance
EARNINGS | Oct 29, 2026, 10:51 AM UTC
M
Merck raises annual profit forecast after third-quarter results exceed expectations
Merck raised its annual profit forecast and reported third-quarter results above expectations. Its shares rose.
EQUITY | Oct 29, 2026, 10:51 AM UTC
M
Merck forecasts FY adjusted EPS of $2.77-$2.82
Merck's FY adjusted EPS outlook is $2.77-$2.82, versus the IBES estimate of $2.65.
EARNINGS | Oct 29, 2026, 10:50 AM UTC
M
Merck Says New Products Drove 5% Q3 2026 Revenue Growth
Merck management said new products drove 5% revenue growth in Q3 2026.
EQUITY | Oct 29, 2026, 10:50 AM UTC
M
Merck Q3 Gardasil Revenue $1,995 Million
EQUITY | Oct 29, 2026, 10:47 AM UTC
M
Merck Reports Q3 Winrevair Sales of $694 Million
EARNINGS | Oct 29, 2026, 10:46 AM UTC
M
Merck Q3 Gardasil Sales $1.995 Billion
EARNINGS | Oct 29, 2026, 10:45 AM UTC
M
Merck Beats Third-Quarter Estimates on Keytruda and Gardasil Strength
Merck exceeded third-quarter estimates, supported by strong performance from Keytruda and Gardasil.
EARNINGS | Oct 29, 2026, 10:45 AM UTC
M
Merck Tops Third-Quarter Expectations as Keytruda and Gardasil Outperform
Merck exceeded third-quarter expectations, with Keytruda and Gardasil performing better than expected.
EARNINGS | Oct 29, 2026, 10:45 AM UTC
M
Merck Q3 Keytruda Revenue: USD 8,600 Million
EQUITY | Oct 29, 2026, 10:43 AM UTC
M
Merck Q3 Revenue Reaches USD 18,085 Million
Merck reported Q3 revenue of USD 18,085 million, versus an IBES estimate of USD 17,313 million.
EQUITY | Oct 29, 2026, 10:39 AM UTC
M
Merck 3Q Keytruda Sales Rise 6%
EARNINGS | Oct 29, 2026, 10:39 AM UTC
L
Merck reports third-quarter net income of $5.07 billion
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck 3Q Januvia and Janumet sales fall 39%
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck Animal Health Sales Rise 4% in 3Q
Merck reported a 4% increase in Animal Health sales in the third quarter.
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck Pharmaceutical Sales Rise 4% in 3Q
Merck reported a 4% increase in pharmaceutical sales in the third quarter.
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck Announces Third-Quarter 2026 Financial Results
Merck said sales growth reflected continued strength in oncology and animal health, plus contributions from Othe
EQUITY | Oct 29, 2026, 10:39 AM UTC
M
Merck Sees FY Revenue of $66.8B-$67.3B
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck Q3 Adjusted EPS $2.49 vs. IBES Estimate $2.08
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck Q3 2026 Net Income Falls 12% to $5.07 Billion
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck shares rise 2.7% premarket after topping third-quarter estimates
EARNINGS | Oct 29, 2026, 10:39 AM UTC
M
Merck supera las previsiones del tercer trimestre
Merck superó las previsiones del tercer trimestre, gracias al buen rendimiento de Keytruda y Gardasil.
EARNINGS | Oct 29, 2026, 10:35 AM UTC
M
Merck Exceeds Third-Quarter Forecasts on Keytruda, Gardasil Results
Merck exceeded forecasts for the third quarter, citing strong results for Keytruda and Gardasil. The body specifically mentions Keytruda.
EARNINGS | Oct 29, 2026, 10:35 AM UTC
M
Merck sets FY revenue outlook at USD 66,800-67,300 million
Merck's FY revenue outlook is USD 66,800-67,300 million, versus an IBES estimate of USD 67,052 million.
EARNINGS | Oct 29, 2026, 10:32 AM UTC
L
Merck Q3 net income was USD 5,065 million
EARNINGS | Oct 29, 2026, 10:32 AM UTC
M
Merck & Co. Reports Q3 EPS of $2.04
EARNINGS | Oct 29, 2026, 10:32 AM UTC
H
$MRK Merck & Co Q3 Earnings
Adj. EPS $2.49, est. $2.07 Rev. $18.09B, est. $17.31B Keytruda rev. $8.60B, est. $8.38B Gardasil rev. $2.00B, est. $1.75B Keytruda Qlex rev. $830M, est. $699.6M Winrevair rev. $694M, est. $643.1M Animal Health sales $1.6
EARNINGS | Oct 29, 2026, 10:31 AM UTC
M
Merck forecasts FY sales of $66.8 billion to $67.3 billion
Merck's full-year worldwide sales outlook is $66.8 billion to $67.3 billion, versus an IBES estimate of $67.03 billion.
EARNINGS | Oct 29, 2026, 10:31 AM UTC
M
Merck Q3 Keytruda Sales Reach $8.60 Billion
EARNINGS | Oct 29, 2026, 10:30 AM UTC
M
Merck Tops Third-Quarter Estimates as Keytruda, Gardasil Outperform
EARNINGS | Oct 29, 2026, 10:30 AM UTC
M
Merck Reports Q3 Loss, Raises Revenue Outlook and Cuts EPS Guidance
Merck reported a non-GAAP loss of $0.13 per share, including a $2.31 per-share charge related to its Terns Pharmaceuticals acquisition. It raised 2026 revenue guidance to $66.3 billion-$67.3 billion and lowered adjusted
EQUITY | Oct 28, 2026, 09:33 PM UTC
M
Merck Expected to Post Slight Q3 Revenue Gain, EPS Decline
A preview says Merck is expected to report a slight year-over-year revenue gain and EPS decline for the third quarter.
EQUITY | Oct 28, 2026, 05:40 PM UTC
M
Merck Q3'26 Earnings Preview: Estimates Ahead of Report
Merck is scheduled to report Q3'26 results on October 29 before the market opens. Revenue and EPS estimates were provided ahead of the report.
EQUITY | Oct 28, 2026, 11:00 AM UTC
H
Merck (MRK) reports Q3: everything you need to know ahead of earnings
Global pharmaceutical company Merck NYSE:MRKwill be reporting earnings this Thursday before market open. Here’s what investors should know.Merck beat analysts’ revenue expectations last quarter, reporting revenues of $16
EQUITY | Oct 28, 2026, 03:07 AM UTC
M
Merck Says Pembrolizumab Cuts Progression and Death Risk 43% in Some Endometrial Cancer Patients
EQUITY | Oct 26, 2026, 05:43 PM UTC